Resources
13 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 2/10/2020 (updated 3/28/2024)
ONDCP released a new tool to assist rural community leaders in building an effective local response to the crisis of addiction, the Rural Community Action Guide: Building Stronger, Healthy Drug-Free Rural Communities. The Guide also has a companion supplement, a listing of promising practices, included.
Posted 5/12/2020 (updated 4/3/2024)
A Tool for Improving The Recruitment and Retention of Critical Access Hospital and Community Health Center Physicians
Posted 5/12/2020 (updated 3/28/2024)
The Clinical Opiate Withdrawal Scale is an 11-item scale designed to be administered by a clinician.
Posted 5/12/2020 (updated 3/28/2024)
The CIWA-Ar assessment for monitoring withdrawal symptoms requires approximately 5 minutes to administer. The maximum score is 67. Patients scoring less than 10 do not usually need additional medication for withdrawal.
Posted 10/12/2020 (updated 3/29/2024)
The Matrix Model is a framework for engaging stimulant(s) users in treatment and helping them achieve abstinence.
Posted 10/23/2020 (updated 4/3/2024)
The American Society of Addiction Medicine (ASAM) developed this National Practice Guideline for the Treatment of Opioid Use Disorder to provide information on evidence-based treatment of opioid use disorder.
Posted 12/9/2020 (updated 4/3/2024)
Detoxification is the process of taking a person off an opioid on which he or she is physically dependent. The detoxification process can be fast or slow. This article describes the advantages and disadvantages of medically supervised withdrawal programs.
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.